KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to -$7.8 million.

  • GoodRx Holdings' Net Cash Flow rose 9229.77% to -$7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$150.2 million, marking a year-over-year increase of 5951.59%. This contributed to the annual value of -$224.0 million for FY2024, which is 16387.73% down from last year.
  • According to the latest figures from Q3 2025, GoodRx Holdings' Net Cash Flow is -$7.8 million, which was up 9229.77% from -$19.7 million recorded in Q2 2025.
  • GoodRx Holdings' Net Cash Flow's 5-year high stood at $32.9 million during Q3 2023, with a 5-year trough of -$147.4 million in Q1 2025.
  • Over the past 5 years, GoodRx Holdings' median Net Cash Flow value was -$7.8 million (recorded in 2025), while the average stood at -$36.7 million.
  • In the last 5 years, GoodRx Holdings' Net Cash Flow soared by 197668.19% in 2023 and then tumbled by 365501.28% in 2024.
  • Quarter analysis of 5 years shows GoodRx Holdings' Net Cash Flow stood at $29.1 million in 2021, then dropped by 2.43% to $28.4 million in 2022, then crashed by 532.04% to -$122.6 million in 2023, then soared by 120.04% to $24.6 million in 2024, then plummeted by 131.7% to -$7.8 million in 2025.
  • Its Net Cash Flow was -$7.8 million in Q3 2025, compared to -$19.7 million in Q2 2025 and -$147.4 million in Q1 2025.